Life Sciences INDUSTRIES

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.


Recognized as a leading life sciences practice, WilmerHale has represented life sciences clients across the United States and Europe for more than four decades. From biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other institutions in the space, including venture capitalists, investment banks, universities and others, we understand the business of our life sciences clients and the changing regulatory and competitive demands they face.

Contacts

Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

stuart.falber@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)

lia.dermarderosian@wilmerhale.com

johnson-brian.jpg

Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

brian.johnson@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Capabilities

WilmerHale's Life Sciences Practice has extraordinary range, and the majority of our lawyers devote a significant portion of their practice to areas critical to life sciences clients. The firm's multi-disciplinary teams work seamlessly to handle a broad range of matters for clients, including corporate finance, licensing and strategic alliances, litigation, mergers and acquisitions, intellectual property, Food and Drug Administration (FDA), competition and other regulatory matters, and securities fraud. Our lawyers advise on venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protect clients' innovations through patent prosecution and portfolio development; and defend their interests in enterprise-critical patent litigation. We also represent life sciences clients in dealings with the United States and other governments on regulatory matters, including issues before the FDA and other agencies, merger clearance and enforcement actions, and public policy and strategy. Read about some of our recent life sciences transactions.

Our Life Sciences Practice includes corporate lawyers who have helped thousands of entrepreneurs successfully launch their businesses; raise billions in financing; and take their companies to sale, the public markets and/or through drug commercialization. We have a longstanding tradition of representing emerging companies and entrepreneurs across industries, and routinely offer the strategic advice and sharp business perspectives that are critical to our clients' success. Learn about our startup practice at WilmerHaleLaunch.com.

Publications & News

View

September 22, 2016

WilmerHale Advises Agios Pharmaceuticals in $173M Public Offering and Full Exercise of Option to Purchase Additional Shares

The WilmerHale team was led by Partner Steven Singer and included Special Counsel Cynthia Mazareas, Senior Associate Mhairi Immermann and Associate Brett Bromann.

September 22, 2016

WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

The acquisition creates a NASDAQ-listed company focused on the development of novel therapies based upon antibody fragments genetically fused to cytotoxic proteins, or targeted protein therapeutics, as new treatments in areas of oncology with significant unmet need.

September 21, 2016

WilmerHale Makes BTI’s IP Litigation Standout List, Fearsome Foursome Honor Roll

The rankings place WilmerHale among the top 20 IP Litigation firms in the industry.

August 29, 2016

Participate in the 2016 CompStudy Survey of Venture-Backed Life Sciences and Technology Companies

WilmerHale invites you to participate in the 2016 CompStudy survey of equity and salary compensation for executives at venture-backed life sciences and technology companies.

July 20, 2016

WilmerHale Advises Aushon BioSystems in $6.14M Series C Financing

Aushon BioSystems, a global provider of protein biomarker measurement and analysis products and services via an innovative, cost-effective multiplex immunoassay platform, announced that it held the initial closing of a $6.14 million Series C Financing.

July 20, 2016

WilmerHale Advises PerkinElmer in €500M Eurobond Offering

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced that it has completed a public offering of €500 million aggregate principal amount of 1.875% Senior Notes due 2026 at an issue price of 99.118% of the principal amount.

July 18, 2016

WilmerHale Advises Intercept Pharmaceuticals in $460M Public Offering

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has announced the closing of an underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023.

July 13, 2016

Civil Fines Jump Across Agencies Under Inflation Adjustment Act

Civil fines across federal agencies have recently been increased dramatically under the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015 (2015 Act) (Sec. 701 of Public Law 114-74), with some more than doubling. Companies violating the Hart-Scott-Rodino (HSR) Improvements Act, the Securities and Exchange Act, or the Occupational Safety and Health Act (OSHA), among others, could soon face civil monetary penalties that are up to 150% higher than the existing levels. According to the Congressional Budget Office, the 2015 Act would increase the federal government's revenue by $1.3 billion over the next ten years.

July 5, 2016

WilmerHale Advises Syros Pharma in Initial Public Offering

WilmerHale advised Syros Pharmaceuticals, Inc., a life sciences company, in its initial public offering.

June 24, 2016

WilmerHale Advises Spark Therapeutics in Public Offering

Spark Therapeutics, Inc. announced the closing of an underwritten public offering of common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission.

Events

October 23-26, 2016

Licensing Executives Society (LES) 2016 Annual Meeting 

Vancouver, Canada

September 20, 2016

WilmerHale's Second Annual Legal Developments Impacting the Life Sciences Industry Conference

New Brunswick, New Jersey

September 19, 2016

GoGlobal DigiHeath: Silicon Valley Mission 2016

Redwood City, California

July 27-29, 2016

American Conference Institute: Women Leaders in Life Sciences Law

Boston, Massachusetts

June 6-9, 2016

Biotechnology Industry Organization: 2016 BIO International Convention

San Francisco, California

June 6, 2016

Best Practices in Strategic Transactions

Cambridge, Massachusetts

May 4-5, 2016

MPM Capital's 15th Annual Healthcare Leaders Summit

Bal Harbour, Florida

March 31-April 1, 2016

The 24th Annual Fordham Intellectual Property Law and Policy Conference

New York, New York

March 30-April 1, 2016

BIO IP Counsels Committee Conference

San Antonio, Texas

March 24, 2016

StartX: Mock Term Sheet Negotiation

Palo Alto, California

Recognition

  • Chambers USA: America's Leading Lawyers for Business - Named WilmerHale a top law firm for life sciences from 2007-2016 and quoted sources as saying our attorneys are "consistently excellent," "very responsive" and "continue to stand out," and that WilmerHale is "a very strong firm" that is "in the top 1%" in the area of life sciences. 
  • Chambers Global - Recognized WilmerHale as a leader in life sciences from 2013-2016 and quoted sources as saying that the firm has an "outstanding US practice coupled with international reach" and "a team of lawyers with a valuable scientific background."
  • Chambers Europe - Recognized WilmerHale as a leader in life sciences in Germany in its 2013-2015 editions.
  • Lake Whillians - Named WilmerHale among the top three Best Life Sciences Law Firms for 2016 in its inaugural Life Science Index, and selected WilmerHale as the top firm in the patent category.
  • Law360 - Named WilmerHale "Life Sciences Practice Group of the Year" for 2013 in its annual competition, which recognizes five firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year.
  • LMG Life Sciences - Ranked the firm in its 2012-2015 editions in the areas of patent prosecution, corporate, and licensing and collaboration, and named the firm a "Lifecycle Firm," regarding WilmerHale as one of the best full-service law firms within the life sciences industry. In 2013, WilmerHale was named the winner of the "Canadian Impact Deals of the Year" award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP - Recognized WilmerHale as one of the best in the United States for life sciences from 2013-2016. In both 2013 and 2016, WilmerHale was named the "Patent Contentious Firm of the Year" and in 2013, the "Pharmaceutical IP Litigation Firm of the Year."
  • The American Lawyer - Placed WilmerHale on its 2015 "A-List" as one of the United States' leading law firms, marking the 12th year the firm received that recognition.
  • The American Lawyer - Recognized WilmerHale as its 2014 "IP Litigation Department of the Year." This was the second time that WilmerHale was named a winner and the third time the firm was named a finalist in this contest since its launch in 2004.
  • The BTI Consulting Group Inc. - Named WilmerHale among the top 10 law firms for having strong and lasting client relationships with the pharma industry in its BTI Power Rankings 2016 report.
  • The Legal 500 US - Ranked WilmerHale among the top law firms for life sciences from 2013-2016 and quoted sources as saying the firm "brings a great deal of experience to any situation" and "has access to additional expertise/resources to help solve any problem."
  • The National Law Journal - Named WilmerHale to its 2012-2015 Intellectual Property Hot List, which honors firms that demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News - Best Lawyers® - Recognized the firm in its 2014-2016 "Best Law Firms" lists in the first tier nationally for biotechnology law, corporate law, intellectual property litigation, patent law, securities, technology law and venture capital law. In 2016, WilmerHale received first-tier metropolitan rankings in Boston and New York for biotechnology law and corporate law; and in Boston, Denver and Washington DC for intellectual property litigation.